Comprehensive Study Guide: Statins and the Mevalonate Pathway

The Mevalonic Pathway and Endogenous Cholesterol Biosynthesis

• Definition of the Mevalonic Pathway: This is the de novo biosynthesis pathway responsible for the internal production of cholesterol within the body.

• Primary Enzyme: HMG CoA Reductase: This specific enzyme is the central component of the mevalonic pathway. Its primary function is to catalyze the conversion of $HMG\,CoA$ into Methylonate.

• Precursor Relationship: Once formed, Methylonate acts as the biochemical precursor for the subsequent steps in the synthesis of cholesterol.

• Rate-Limiting Property: The HMG CoA reductase enzyme is characterized by its rate-limiting property, acting as the primary regulatory control for cholesterol synthesis:     - Excess Cholesterol: If the body possesses too much cholesterol, the enzyme is "switched off" to halt or reduce synthesis.     - Insufficient Cholesterol: If cholesterol levels are low, the body produces more of this enzyme to increase the efficiency of the biochemical process and synthesize more cholesterol in the liver.

• Dyslipidemia Implication: In patients suffering from dyslipidemia, this mevalonic pathway is interrupted. The HMG CoA reductase enzyme fails to effectively regulate and maintain appropriate cholesterol levels.

Mechanism of Action: Inhibition of HMG CoA Reductase

• Competitive Inhibition: Statins work by acting as competitive inhibitors of the HMG CoA reductase enzyme. By inhibiting this enzyme, they effectively block the mevalonate pathway and the synthesis of endogenous cholesterol.

• Structural Mimicry: Older statins exhibit a chemical structure that is structurally similar to the endogenous $HMG\,Coenzyme\,A$.

• Binding Process: Due to this similarity, statins bind exactly to the active site of the HMG CoA reductase enzyme, just as the endogenous substrate would.

• Catalytic Interruption: Once the statin binds to the active site, it physically halts the catalytic reaction that would otherwise form Nasalonate, thereby preventing cholesterol production.

Statin Varieties and Clinical Prevalence in Australia

• Prevalence: Statins are among the most frequently used medications. In Australia, Atavastatin and Rosovastatin are the top $2$ most commonly prescribed medications, highlighting the significant incidence of dyslipidemia in the country.

• Available Statin Agents: There are $5$ different HMG CoA reductase inhibitors utilized in Australia:     - Atavastatin     - Rosovastatin (also referred to as Rosuvastatin)     - Simvastatin     - Prevastatin     - Fruvastatin (noted as being less commonly used in clinical practice).

• Class Uniformity: While these drugs differ in certain pharmacological nuances, all share the same fundamental mechanism of action.

Physiological Response: LDL Receptor Expression and Lipid Reduction

• Hepatocellular Sensing: When statins reduce endogenous cholesterol levels, hepatocytes (liver cells) perceive a deficiency in the cholesterol needed for bodily functions.

• Increased Receptor Expression: To compensate, hepatocytes increase the expression of LDL receptors.

• Surface Transport: These receptors are transported to the surface of the liver cells to interact with the systemic circulation.

• Systemic Clearance: The increase in surface receptors allows more LDL lipoproteins to be taken up from the blood into the liver, which significantly reduces the levels of LDL cholesterol in the system.

• VLDL Inhibition: Statins also inhibit the production of $VLDL$. Normally, $VLDL$ packages and transports triglycerides and cholesterol into systemic circulation. The reduction of endogenous cholesterol in the liver inhibits this packaging process.

• Collective Impact: The combined effect of these processes is a measurable decrease in both LDL lipoproteins and overall triglyceride levels.

Pleiotropic Effects and Cardiovascular Health

• Hypothesized Benefits: Statins offer cardiovascular health benefits that extend beyond simple lipid lowering, although the exact mechanisms are not entirely understood.

• The dietherpin Branch: Halfway through the mevalonic pathway, certain biochemicals can synthesize a dietherpin known as Geranylgyranil pyrophosphate.

• Protein Prenulation: Geranylgyranil pyrophosphate is critical for protein-protein binding, a process termed protein prenulation.

• Impact on Health: Current research suggests that an increase in protein prenulation is a contributing factor to poor cardiovascular health.

• Cardiovascular Protection: By inhibiting the mevalonate pathway, statins also inhibit the production of these diterpin branches, thereby reducing protein prenulation and improving overall cardiovascular health.

Adverse Drug Reactions: Spectrum of Statin-Induced Myopathy

• Introduction to Myopathy: Myopathy refers to disorders of the muscles and is the most common adverse effect associated with the use of statins.

• Clinical Classifications of Myopathy:     - Myalgia: Characterized by muscle pain. This is common but is not considered life-threatening.     - Myositis: Characterized by physical inflammation of the muscles.     - Rhabdomyolysis: Characterized by the destruction of striatum muscle cells. This is a rare but life-threatening condition.

• Histological Observations:     - Normal Skeletal Muscle: Displays healthy cells with well-defined borders.     - Statin-Induced Myositis: Most cells appear inflamed, though many still retain their defined borders.     - Statin-Induced Rhabdomyolysis: Shows complete disruption of cells, which lose their defined borders compared to normal tissue.

Metabolic and Clinical Consequences of Rhabdomyolysis

• Systemic Release: The destruction of muscle cells in rhabdomyolysis causes the release of several substances into the systemic circulation in excessive amounts, including:     - Myoglobin     - Potassium ($K^+$)     - Creatinine kinase

• Kidney Damage: Substances such as myoglobin and creatinine kinase can lead to severe renal damage by scarring the nephrons.

• Cardiac Arrest Risks: Excessive potassium levels ($K^+$) can alter the heart's action potential, leading to an increased risk of arrhythmia and potentially fatal cardiac arrest.

Pathophysiological Theories of Statin-Induced Muscle Damage

• The Weakened Membrane Theory: This theory suggests that statins cause a decrease in cholesterol levels in the muscle and brain. Since muscle membranes are composed of cholesterol to maintain structural integrity, a reduction leads to weakness. However, this does not explain why other cell types remain unaffected.

• The Coenzyme q 10 and Prenulation Theory: This hypothesis suggests that a decrease in protein prenulation and a reduction in $Coenzyme\,q\,10$ (known as ubiquinone) damages the skeletal muscles. $Coenzyme\,q\,10$ is a vital enzyme in the mitochondria; its depletion may make the muscle membrane highly susceptible to damage.

• The Autoimmune Theory: More recent findings suggest that statin-induced myopathy might be triggered by a specific autoimmune reaction, though this remains an area of ongoing study.

Systemic Adverse Effects and Liver Enzyme Monitoring

• Gastrointestinal Symptoms: Statins can cause mild $GI$ issues, such as stomach upset.

• Neurological Symptoms: Headaches may occur, though these incidents are typically mild.

• Hepatic Enzyme Elevation: Statins may cause a slight increase in liver enzymes. The four main enzymes monitored are:     - $ALT$     - $AST$     - $ALP$     - $GGT$

• Liver Function Tests (LFTs): These enzymes are tracked via $LFTs$. A slight elevation is common because statins are metabolized by the $CYP450$ system in the liver. However, consistent and significant elevation signals inflammation and a risk of hepatotoxicity.

Pharmacokinetic Variations and Timing of Administration

• Short Half-Life Statins: Includes Prevastatin and Simvastatin.

• Long Half-Life Statins: Includes Rosuvastatin and Atavastatin.

• Administration Timing:     - Long Half-Life: These can be taken at any time (morning or night) because their long duration of action maintains efficacy throughout the day.     - Short Half-Life: These must be taken specifically at nighttime.

• Rationale for Nighttime Dosing: The synthesis of endogenous cholesterol is at its peak when the body is at rest during the night. For statins with a short half-life, evening administration is required to ensure the drug is present to inhibit the mevalonate pathway during this peak period of cholesterol production.